Myosin Therapeutics has been awarded $2 million in funding to support a Phase 1/2 clinical trial testing its lead experimental cancer therapy, MT-125, in…

Overt Bio said it established a clinical advisory board to support the development of OVT-101, its lead investigational CAR T-cell therapy for ovarian cancer,…

Have you ever heard something like this after telling someone you have multiple myeloma? “Oh, my uncle had that! It was on his nose!”…